Elan and Biogen show MS QoL improvement

Elan and Biogen has announced that patients with multiple sclerosis (MS) experienced an improvement in health related quality of life (QoL) during phase III trials of Tysabri.

Two separate phase III trials carried out using Tysabri assessed QoL in three ways: the multiple sclerosis quality of life inventory (MSQLI), the short form-36 health survey (SF-36) and a visual analogue scale (VAS).

Both physical and mental improvement was noted in the patients administered the Tysabri drug, whereas a decline in both areas was noted in the placebo group. In fact, QoL was notably improved in data from all three measurement methods.

“We have never before observed positive findings on our quality of life measures in a phase III MS study,” said Dr Richard Rudick, director of the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic.

“The Tysabri study data shows not only significant reductions in relapses and disability, but also suggests improved quality of life. This is very encouraging.”

Dr Rudick presented the findings of the trials at the American Academy of Neurology Annual Meeting, where it was also revealed that the group treated with the drug showed a reduced risk of visual decline associated with MS.

© Adfero Ltd